Reuters logo
BRIEF-AC Immune partner Genentech presents important data on Alzheimer's Therapy Crenezumab
December 9, 2016 / 9:20 PM / 9 months ago

BRIEF-AC Immune partner Genentech presents important data on Alzheimer's Therapy Crenezumab

Dec 9 (Reuters) - AC Immune Ltd

* AC Immune partner Genentech presents important data on Alzheimer’s Therapy Crenezumab

* AC Immune - Crenezumab higher dose in CREAD Phase 3 Alzheimer’s trial supported by exposure-response model Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below